Controversy over the role of fibrinolysis in patients with intermediate-risk pulmonary
embolism (PE) has persisted because of the lack of adequately sized trials. The PEITHO …

Background The role of fibrinolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. Methods In a randomized, double-blind trial, we compared …

To the Editor: In the Pulmonary Embolism Thrombolysis (PEITHO) study (April 10 issue), 1 a
bolus of unfractionated heparin was withheld from 303 patients because they had just …

We have recently read with great interest the article by Sanchez et al entitled “Reduced-
dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism …

Purpose Current literature on clinical controversies surrounding the use of thrombolytic
agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. Summary …

Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

Background Submassive pulmonary embolism (PE) has a low mortality rate but can degrade
functional capacity. Objective The present study aims to provide rationale, methodology, and …

Acute pulmonary embolism (PE) presents as a constellation of clinical syndromes with a
variety of prognostic implications. Patients with acute PE who have normal systemic arterial …

The use of fibrinolytic agents in acute pulmonary embolism (PE), first described over 50
years ago, hastens the resolution of RV stain, leading to earlier hemodynamic improvement …

In April 2022, Boehringer Ingelheim announced that its production capacity for recombinant
tissue–type plasminogen activator will, for a variety of reasons, be unable to meet the current …